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the US Centers for Disease Control and Prevention recently claimed that more than 1 in 3 American adults have blood sugar levels that are too high.1 They included prediabetics 
in their statement.
In 2016, the University of California, Los Angeles (UCLA), 
reported that 55% of Californian adults are either prediabetic 
or have undiagnosed type 2 diabetes (Figure 1).2 Prediabetes 
is not a nit-picking philosophical concept. Diabetic 
pathologies develop during prediabetes3 and, by the time type 
2 diabetes manifests itself, patients may already have kidney 
impairment,4,5 vision loss,6-8 neuropathy,9 atherosclerosis10-12 
and cancer.13-15 Excessive food and drink intake, particularly 
the high glycaemic ones, spike blood sugar levels which also 
accelerate ageing by shortening telomeres.16,17
The goalposts for safe blood glucose levels have been 
changing. Levels considered dangerous now were thought to be 
safe decades ago. Current recommendation is for blood sugar to 
be kept at the low end of the normal reference range.18-21 However, 
a significant section of the medical community may have failed to 
wake up to the life-shortening impact of prediabetes.
One diagnostic problem is that prediabetes and early 
stage diabetes may be missed by the standard fasting blood 
glucose in the presence of hyperinsulinaemia. As long as there 
is reasonable insulin sensitivity and hyperinsulinaemia, a 
fasting blood glucose may appear to be in a safe range, which 
is conventionally considered to be under 5.6 mmol/L, although 
some claim the safe upper limit ought to be 4.7mmol/L.
Hyperinsulinaemia contributes to disease states (e.g. 
hypertension, blood hypercoagulability and increased 
cancer risk) even before fasting blood glucose rises to what 
conventional medicine regards as prediabetic levels, namely, 
5.6 – 6.9 mmol/L. For the above reasons, and in this scenario, 
the fasting blood glucose test should perhaps now be 
considered dangerously obsolete.
The haemoglobin A1c (HbA1c) blood test provides a better 
picture of glycaemic control than fasting blood glucose,22 but 
is probably underutilised in identifying prediabetes. The safe 
upper limit for HbA1c is considered 5.5%, but lower ranges 
have been shown to be healthier.23 HbA1c between 5.6% and 
6.4% is diagnostic for prediabetes.24 
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Metformin ought to be prescribed when the HbA1c is 
between 5.6% and 6.4% for prevention of type 2 diabetes,25 
together with advice on calorie restriction and, in particular, 
the high glycaemic ones. Metformin enhances insulin 
sensitivity and functions via several mechanisms to improve 
glycaemic control.26-30 It has proven ability to delay or prevent 
type 2 diabetes.31-33 Yet recent US surveys reveal it is prescribed 
to only 3.7% to 8.1% of prediabetics.33-35 
Perhaps the term prediabetes is a misnomer because 
even modestly elevated glucose levels inflict microvascular 
damage resembling the long-term complications of type 
2 diabetes.36,37 Excess glucose is converted to triglycerides 
that are stored as fat (subcutaneous and abdominal) and 
which may result in fatty liver disease (may progress to 
cirrhosis and hepatocellular carcinoma). Excess glucose 
is inflammatory to many tissues, including arteries 
(atherosclerosis).38-40 High “normal” blood sugar levels 
are increasingly recognised as posing an increased risk of 
degenerative disorders.4-15,20,41-49 
Fasting blood glucose values in the upper “normal” range 
(above 4.7mmol/L) appear to be an important independent 
predictor of cardiovascular death in nondiabetic, apparently 
healthy, middle-aged men.18 After-meal glucose levels are an 
even stronger predictor of disease risk.50-52
About 70% of prediabetics will develop type 2 diabetes 
in their lifetime.53,54 It is misleading to think that prediabetes 
relates to a period where no diabetic damage is caused. 
Coronary heart disease risk is similar between prediabetics 
and type 2 diabetics.47
now, statins. In spite of the huge global expense on cholesterol 
testing and statins, atherosclerotic-related morbidity and 
mortality remains number one in industrialised countries. 
The clinical significance of the various blood 
lipoproteins is still confused. We now know that there are 
at least two main types of LDL cholesterol, a small, dense 
atherogenic particle and a larger lighter one thought to be 
harmless. The different LDL particles are too expensive to 
be measured routinely. We therefore don’t know whether 
a high LDL is due to an elevated “harmless” or “bad” LDL 
sub-fraction. Adding “non-HDL cholesterol” to routine 
testing is even more confusing. The combination of a 
raised fasting triglycerides level and a low HDL level is 
a surrogate marker for raised “bad” LDL (see previous 
features in the The Synapse Journal on the Cholesterol 
Controversy). What raises fasting triglycerides levels and 
lowers HDL are high glycaemic carbohydrates and alcohol, 
rather than saturated fats. 
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Early detection of prediabetes means a greater 
likelihood of reversing it before it progresses to type 
2 diabetes. Glucose-lowering approaches should be 
initiated when HbA1c exceeds 5.5% and not delayed till 
it reaches 6.5%.
In the area of laboratory predictive testing for 
cardiovascular risk, we have probably underestimated the 
importance of the prediabetic state (as defined by HbA1c 
levels above). For around 60 years we accepted the hype 
around cholesterol, dietary saturated fats, heart attacks and 
Glucose may be a more important damaging 
inflammatory agent than saturated fats. The French have 
the lowest heart disease mortality in Europe (and second 
lowest worldwide). Malta has almost three times the heart 
disease mortality of France. The reason is not Maltese 
consumption of dairy produce and meats being three times 
that in France. Obesity and blood glucose levels might be the 
main problem, rather than cholesterol. Perhaps about half 
our adult population is prediabetic or already diabetic, like 
California. Who knows?
The term “prediabetes” may render a false sense 
of normality. Perhaps the progression stages of type 2 
diabetes could more realistically be renamed, “early 
diabetes”, “established diabetes” and “end-stage (insulin-
dependent) diabetes”. A false sense of normality is also 
fostered by laboratories in Malta stating a “normal range” 
for HbA1c of up to 6.5%, when it should be up to 5.5%. 
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Figure 1: Diabetes cases by age group. 
A UCLA study found that 55% of adults in 
California have either diabetes or prediabetes.2
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